Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

NCT02819583 is registered in ClinicalTrials.gov with PersonGen BioTherapeutics (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT02819583
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02819583 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
Lead sponsor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 31, 2016
Completion date
September 30, 2019
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphocytic leukemia, b-cell prolymphocytic leukemia, chronic lymphocytic leukemia, diffuse large cell lymphoma, follicular lymphoma, mantle cell lymphoma